健帆生物 reported revenue of ¥1.03B for the period ended 2026-06-30, -9.0% year on year. Net income was ¥0.38B, a 37.1% net margin on a 78.5% gross margin. The largest revenue line is 一次性使用血液灌流器 at 84% of the total. Free cash flow for the period was ¥0.11B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.03B | -9.0% |
| Gross profit | ¥0.81B | — |
| Operating income | ¥0.45B | — |
| Net income | ¥0.38B | -1.5% |
| Gross margin | 78.5% | Net margin 37.1% |
| Revenue Q/Q | -15.8% | — |
| Segment | Revenue | Share |
|---|---|---|
| 一次性使用血液灌流器 | ¥0.87B | 84.1% |
| 其他主营业务 | ¥0.16B | 15.6% |
| 其他(补充) | ¥0.00B | 0.3% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.22B | 21.5% |
| R&D | ¥0.10B | 10.0% |
| SG&A | ¥0.23B | 22.5% |
| Tax & other | ¥0.07B | 6.7% |
| Item | Amount |
|---|---|
| Total assets | ¥5.20B |
| Total liabilities | ¥1.74B |
| Shareholders' equity | ¥3.46B |
| Equity / assets | 66.6% |
| Operating cash flow | ¥0.16B |
| Capital expenditure | ¥0.04B |
| Free cash flow | ¥0.11B |
| Cash conversion (OCF / net income) | 107% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
领湃科技 ・ 优博讯 ・ 今天国际 ・ 冰川网络 ・ 陇神戎发 ・ 达威股份 ・ 农尚环境 ・ 广信材料 ・ 同益股份 ・ 横河精密 ・ 蜀道装备 ・ 先进数通
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies